BiotechTube

ranibizumab + triamcinolone acetonide

Phase 2/3UNKNOWN
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveal Melanoma

Conditions

Uveal Melanoma

Trial Timeline

Sep 1, 2009 → —

NCT ID
NCT00811200

About ranibizumab + triamcinolone acetonide

ranibizumab + triamcinolone acetonide is a phase 2/3 stage product being developed by Novartis for Uveal Melanoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00811200. Target conditions include Uveal Melanoma.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00811200Phase 2/3UNKNOWN

Competing Products

20 competing products in Uveal Melanoma

See all competitors
ProductCompanyStageHype Score
Pembrolizumab + LenvatinibEisaiPhase 2
52
Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mgAstraZenecaPhase 1
33
Pembrolizumab + EntinostatMerckPhase 2
52
Pembrolizumab + OlaparibMerckPhase 2
52
Pembrolizumab 25 MG/1 ML Intravenous SolutionMerckPhase 2
52
AEB071NovartisPhase 1
33
LXS196 + LXS196 and HDM201NovartisPhase 1
33
DYP688NovartisPhase 1/2
41
RAD001 (Everolimus) and Pasireotide (SOM230) LARNovartisPhase 2
52
CrizotinibPfizerPhase 2
51
Dacarbazine + SunitinibPfizerPhase 2
51
AEB071 + MEK162PfizerPhase 1/2
40
Binimetinib + BelinostatPfizerPhase 2
51
Ipilimumab + NivolumabBristol Myers SquibbPhase 1
32
Nivolumab + RelatlimabBristol Myers SquibbPhase 2
51
ipilimumab + NivolumabBristol Myers SquibbPhase 2
51
ZIV-Aflibercept + CemiplimabSanofiPhase 2
51
Ziv-AfliberceptRegeneron PharmaceuticalsPhase 2
51
XmAb®23104 + Yervoy® (ipilimumab)ICON plc.Phase 1
30
IDE196 + Binimetinib + CrizotinibIDEAYA BiosciencesPhase 1/2
36

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85